Compare IDEXX Laboratories, Inc. (IDXX) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs MobilEye Global Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while MobilEye Global Inc trades at $8.87 (market cap $7.54B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.1× MobilEye Global Inc's market cap. Which is the better fit depends on your goals.
| IDXX | MBLY | |
|---|---|---|
Market Cap | $46.22B | $7.54B |
Sector | Health | Technology |
52-Week High | $766.68 | $15.54 |
52-Week Low | $526.44 | $6.56 |
Enterprise Value | $47.12B | $6.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Mobileye (MBLY) trades at $8.80, up 0.57% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat estimates with EPS of $0.19 versus $0.06 expected, driven by an R&D grant, while revenue reached $508 million (Bloomberg, 2026-07-23). The company faces leadership transition as CEO Amnon Shashua steps down after 27 years, amid expanded robotaxi and ADAS initiatives, including a new supply deal with Stellantis (Business Wire, 2026-07-21).
Outlook: Analyst consensus is bullish with a $11.40 price target (61.5% buy ratings), but risks include persistent net losses (-$4.1B in 2026), high EV/EBITDA of 43.25, and execution challenges under new leadership. The stock offers upside if robotaxi adoption accelerates, but profitability concerns and market volatility pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
